Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. March 27, 2018 ARTICLE CITATION DOI: 10.1200/JCO.2018.78.7390 Journal of Clinical Oncology - published online before print June 12, 2018 PMID: 29894272 Deleting Malignant B Cells With Second-Generation Anti-CD20 Antibodies Josh SoppxJosh SoppSearch for articles by this author and Mark S. CraggxMark S. CraggSearch for articles by this author Show More Josh Sopp and Mark S. Cragg, University of Southampton, Southampton, United Kingdom https://doi.org/10.1200/JCO.2018.78.7390 First Page Full Text PDF Figures and Tables © 2018 by American Society of Clinical Oncology Original Article Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
No takes yet. Share an insight, caveat, or question.
Sopp et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: